Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

543 ARTÍCULOS , VIENDO DEL 271 AL 285

New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs

Katsenos AP, Davri AS, Simos YV, Nikas IP, Bekiari C, Paschou SA, Peschos D, Konitsiotis S, Vezyraki P, Tsamis KI.

Expert Opin Investig Drugs. 2022 Jan;31(1):105-123. doi: 10.1080/13543784.2022.2022122. Epub 2022 Jan 2.

Effects of Medicare comprehensive medication review on racial/ethnic disparities in nonadherence to statin medications among patients with Alzheimer's Disease: an observational analysis

Browning JA, Tsang CCS, Dong X, Wan JY, Chisholm-Burns MA, Finch CK, Tsao JW, Liu C, Wang J.

BMC Health Serv Res. 2022 Feb 7;22(1):159. doi: 10.1186/s12913-022-07483-8.

AD and its comorbidities: An obstacle to develop a clinically efficient treatment?

Baker J, Schott JM.

Rev Neurol (Paris). 2022 May;178(5):450-459. doi: 10.1016/j.neurol.2022.03.001. Epub 2022 May 2.

Association Between Metformin and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies

Luo A, Ning P, Lu H, Huang H, Shen Q, Zhang D, Xu F, Yang L, Xu Y.

J Alzheimers Dis. 2022;88(4):1311-1323. doi: 10.3233/JAD-220180.

Recruitment and Screening Methods in Alzheimer's Disease Research: The FIT-AD Trial

Greimel S, Wyman JF, Zhang L, Yu F.

J Gerontol A Biol Sci Med Sci. 2022 Mar 3;77(3):547-553. doi: 10.1093/gerona/glab092.

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, Wang G, Singhal P, Budd Haeberlein S, Smirnakis K.

JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.

Theranostic Applications of Nanomaterials in Alzheimer's Disease: A Multifunctional Approach

Tripathi P, Shukla P, Bieberich E.

Curr Pharm Des. 2022;28(2):116-132. doi: 10.2174/1381612827666211122153946.

The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review

Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y.

J Alzheimers Dis. 2022;85(3):1195-1204. doi: 10.3233/JAD-215423.

Stem Cell-based Therapeutic and Diagnostic Approaches in Alzheimer's Disease

Abdi S, Javanmehr N, Ghasemi-Kasman M, Bali HY, Pirzadeh M.

Curr Neuropharmacol. 2022;20(6):1093-1115. doi: 10.2174/1570159X20666211231090659.

Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities

Ismail Z, Creese B, Aarsland D, Kales HC, Lyketsos CG, Sweet RA, Ballard C.

Nat Rev Neurol. 2022 Mar;18(3):131-144. doi: 10.1038/s41582-021-00597-3. Epub 2022 Jan 4.

Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease

Heilman KM, Nadeau SE.

Neurotherapeutics. 2022 Jan;19(1):99-116. doi: 10.1007/s13311-021-01172-w. Epub 2022 Jan 10.

Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials

Duara R, Barker W.

Neurotherapeutics. 2022 Jan;19(1):8-25. doi: 10.1007/s13311-022-01185-z. Epub 2022 Jan 27.

Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease

Andrade C.

J Clin Psychiatry. 2022 Feb 1;83(1):22f14398. doi: 10.4088/JCP.22f14398.

Strategic Design of Amyloid-β Species Fluorescent Probes for Alzheimer's Disease

Su D, Diao W, Li J, Pan L, Zhang X, Wu X, Mao W.

ACS Chem Neurosci. 2022 Mar 2;13(5):540-551. doi: 10.1021/acschemneuro.1c00810. Epub 2022 Feb 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias